Clinical Research Directory

Inclusion Criteria: 1. Participants must be at least 18 years old, male or female. 2. Participants must be diagnosed with NSAA and have a refractory/relapsed/intolerable response to standard-dose cyclosporine (CsA). The definition of refractory/relapsed is patients who have been treated with sufficient doses of cyclosporine (3-5mg/kg) for at least 6 months without response or relapse. The definition of intolerable is patients who cannot tolerate CsA and have stopped treatment due to significant side effects. 3. Participants must meet the following criteria at enrollment: platelets \<30×109/L. 4. Baseline liver and kidney function must be within 2 times of normal range. 5. No active infection; no pregnancy or breastfeeding. 6. Participants must agree to sign the informed consent form. 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Exclusion Criteria: 1. Other causes of pancytopenia, such as myelodysplastic syndrome (MDS). 2. Evidence of clonal hematopoietic system bone marrow disease (MDS, AML) with cytogenetics. 3. PNH clone ≥50%. 4. Received hematopoietic stem cell transplant (HSCT) prior to enrollment. 5. Received ATG treatment within 6 months prior to enrollment. 6. Infection or bleeding that cannot be controlled with standard therapy. 7. Allergic to ruxolitinib. 8. Active HIV, HCV, or HBV infection, cirrhosis, or portal hypertension. 9. Any malignant tumor within 5 years, or local basal cell carcinoma of the skin. 10. History of thromboembolic events, myocardial infarction, or stroke (including antiphospholipid syndrome) and current use of anticoagulants. 11. Pregnant or breastfeeding (lactating) women. 12. Participated in another clinical trial within 3 months.